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Abstract
Background: Malignant Ascites (MA) is a therapeutic dilemma significantly impairing patients’ quality of life (QoL).
The Sequana Medical alfapump System (AP), a subcutaneous, externally rechargeable, implantable device, continually
draining ascites via the urinary bladder, has been well established in liver cirrhosis, but not yet in MA. The AP-system
was evaluated in cancer patients in reducing the need for large volume paracentesis (LVP).
Methods: A retrospective multicentre evaluation of all eligible patients who received an AP for MA-palliation was
performed. AP was evaluated for its ability to reduce LVP and cross-correlated with adverse events (AE), survival and
retrospective physician-reported QoL.
Results: Seventeen patients with median age of 63 years (range: 18–81), 70.6% female, across 7 primary tumour types
were analysed. Median duration of AP-implantation was 60min (range: 30–270) and median post-implantation hospital
stay: 4 days (range: 2–24). Twelve protocol-defined AE occurred in 5 patients (29.4%): 4 kidney failures, 4 pump/catheter-
related blockages, 3 infections/peritonitis and 1 wound dehiscence. Median ascitic volume (AV) pumped daily
was 303.6 ml/day (range:5.6–989.3) and median total AV drained was 28 L (range: 1–638.6). Median patient
post-AP-survival was 111 days (range:10–715) and median pump survival was 89 days (range: 0–715). Median
number of paracenteses was 4 (range: 1–15) per patient pre-implant versus 1 (range: 0–1) post-implant (p = 0.005). 71%
of patients were reported to have an improvement of at least one physician reported QoL-parameters.
Conclusions: AP appears to be effective in palliating patients with MA by an acceptable morbidity profile. Its broader
implementation in oncology services should be further explored.
Trial registration: NCT03200106; June 27, 2017.
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Background
Malignant Ascites (MA) is a common complication of
peritoneally disseminated cancers and a therapeutic
dilemma significantly impairing affected patients’ quality
of life (QoL) [1]. MA often requires repetitive paracenteses
to alleviate symptoms such as abdominal distension and
discomfort, shortness of breath, and gastrointestinal symp-
toms [2]. The most common malignancies associated with
recurrent MA include ovarian-, breast-, colorectal-, gastric-
and unknown primary cancer [2]. The principal aetiology
of MA seems to be attributed to the reduced resorption of
peritoneal fluid via the peritoneal lymphatic system due to
the peritoneal carcinomatosis. Additional potential findings
such as liver parenchyma- or porta hepatis metastases
aggravate the overall clinical picture [2, 3].
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The development of MA is usually a prognostically
unfavourable sign with often limited therapeutic options
[4]. Management is usually symptomatic including para-
centesis and diuretics, while cytotoxic and targeted
agents aim at reducing the tumour burden and hence in-
directly the production of malignant fluid. In patients
with advanced disease and high tumour burden, MA
often requires repetitive large volume paracentesis (LVP)
which is usually performed under sonographic guidance
and has been shown to be effective and feasible in an
out- or inpatient setting, depending on the overall clin-
ical picture of the patient [5, 6]. Alternatively, MA may
be managed via the placement of a permanent subcuta-
neous catheter, such as the PleurX, which is an approved
treatment modality for MA from various national orga-
nisations like the UK based National Institute for Health
and Care Excellence (NICE) [7, 8]. Nevertheless, the re-
petitive puncture and drainage of the peritoneal cavity of
patients with disseminated peritoneal carcinomatosis, in
addition to being debilitating for the patient, is also asso-
ciated with significant potential risks such as bowel re-
lated complications, port/drain related complications
and infections. For these reasons, alternative manage-
ment options are warranted to minimise risk, alleviate
symptoms, and most importantly improve patients’ QoL
in this highly palliative situation.
Intra-peritoneal application of the anti-Epcam anti-
body Catumaxomab had been licensed for MA by the
EMA in 2009, however the product has been withdrawn
from the US and EU markets in 2013 and 2017, respect-
ively and is not marketed in EU since 2014. Moreover,
not all patients were candidates for this treatment, since
immunoreaction to the drug often led to an inflamma-
tory response, with pyrexia, nausea, vomiting, abdominal
pain and elevated inflammation markers [9].
The Alfapump (AP) System (Sequana Medical, Zürich,
Switzerland) is a fully implantable subcutaneous device
with a rechargeable battery that moves ascitic fluid from
the peritoneal cavity to the urinary bladder from where
it is drained by spontaneous diuresis. The AP offers an
alternative therapeutic option in terms of a continuous
ascitic drainage. This technology was initially developed
for cirrhotic patients with refractory ascites and has
shown a 90% reduction of ascites with a significant re-
duction in the requirement of LVP [10]. Due to the
completely different pathophysiology, aldosterone antag-
onists and diuretics do not work, and so novel treat-
ments for MA are of importance. To date, no systematic
evaluation of cancer patients with MA treated with the
AP is available in the literature; although, a positive case
has been reported by Storni et al. [11].
In this retrospective study, we evaluated the perform-
ance of the AP in reducing the need for LVP in MA as
well as its safety and tolerability.
Methods
Study design
This is a retrospective, multicentre study to assess the
safety and efficacy of the AP in the palliation of patients
with MA. The study involved 6 sites across 3 countries
i.e. Germany, Switzerland and the UK. Patients 18 years
or older who had undergone an implantation of the AP
System for palliative management of their MA between
January 2013 and November 2016 were eligible. Patient
medical records, implant reports and pump log files
were reviewed to obtain data including demographics,
history of disease, medical history, pre-implant paracen-
tesis events (number and volume) implant procedure
characteristics, post-implant paracentesis/drainage
(number and volume), occurrence of medical and tech-
nical safety events, antineoplastic treatments and QoL
measurements.
The primary endpoint of the study was time to first
LVP (defined as therapeutic paracentesis ≥5 L) after AP-
implantation. Secondary endpoints included the need of
any volume paracentesis, the change in frequency and
volume of post-implant LVP compared to the preim-
plantation period; total ascites volume drained by the
AP, device related complications, pump- and patient
survival and duration of hospitalisation after the proced-
ure. Adverse events of interest were retrospectively de-
fined and assessed and are stated in full detail in the
supplement of this paper (Additional file 1: Table S1).
They include obstructive uropathy, ascites leakage de-
fined as a flow of ascitic fluid from the peritoneal cavity
to outside the body along the catheter or surgical inci-
sions, or into subcutaneous tissue (early ≤7 days post,
late > 7 days post implant), wound dehiscence, pump
pocket filled with ascites, not controlled ascites, and
pump pocket ulceration.
Exploratory endpoints included subsequent, post-
implantation anticancer treatments and assessment of
effect of treatment on quality of life (QoL), as retrospect-
ively measured by a physician-assessed questionnaire at
the time of patient chart review (Additional file 1: Table
S2). As QoL was an exploratory endpoint, the question-
naire was developed by Sequana and was not validated
in a patient’s cohort. The treating physician was asked to
review the medical records for effect of treatment on the
patient’s tiredness, abdominal pain, sleeping, bloating,
shortness of breath, appetite, nutritional status and over-
all status as worsened, no change, improved or indeter-
minate at the time of collection of the data.
Device and procedure description
The AP system is a commercially available product con-
sisting of three implantable components: a subcutaneous
battery powered pump that is recharged through the
skin, a catheter that transfers ascites from the peritoneal
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cavity into the pump, and a further catheter that pumps
the ascites from the AP into the bladder. The AP is fully
implanted using minimally invasive surgical techniques
and allows normal patient mobility and activity as there
are no percutaneous components. The pump battery is
charged inductively through the skin using a handheld
charger and the AP programmer allows the clinician to
wirelessly (through the charger) adapt the system param-
eters to optimize fluid management according to indi-
vidual patient needs.
The implantation procedure has previously been de-
scribed in detail by Stirnimann et al. [10]. In summary,
the bladder is being filled with methylene blue-coloured
saline solution to facilitate the adequate suprapubic
insertion of the AP- bladder catheter. The peritoneal
catheter is then tunnelled till the entry point into the
abdomen, followed by the subcutaneous positioning of
the pump in the right or left upper quadrant below the
costal margin.
Statistical methods
A descriptive analysis was performed. Categorical vari-
ables are described using frequencies and percentage of
each category. Continuous variables are described using
the means, medians, standard deviation or range of each
distribution. The analyses were performed in SAS Ver-
sions 9.3 or higher (SAS Institute, Cary, USA) and Excel
2016 (Microsoft, Redmond, WA, USA).
Patient survival was calculated by the Kaplan Meier
method as days from AP-implantation to patient’s death,
or if the patient was still alive, till the date of the last fol-
low up. Pump survival was calculated as days from pump
implantation to either device explantation or patients last
follow up or death if the pump remained in situ.
Ethics
The study was approved by the governing ethics com-
mittee of each centre and conducted in accordance with
ethical and Good Clinical Practice guidelines. An ex-
emption of informed consent was granted for those sub-
jects that were deceased. Informed consent was obtained
from those patients that were alive.
Results
A total of 17 patients were included in the present retro-
spective analysis. The majority of the patients were
female (n = 12; 70.6%). Fifteen (88.2%) patients were
deceased at the time of the study analysis. The median
age at implantation was 63 years (range: 18–81).
Primary malignancy was of hepatic origin in 6 patients
(35.3%), epithelial ovarian cancer in 5 patients (29.4%),
breast-, uterine-, renal- and pancreatic cancer in 1
patient (5.9%) each and primary cholangiocarcinoma in
2 further patients (11.8%).
Main patients’ comorbidities were cardiovascular
(64.7%; n = 11), metabolic/nutritional (42.2%; n = 7),
hepatobiliary (29.4%; n = 5), haematologic (17.6%; n = 3)
and gastrointestinal (17.6%, n = 3). Table 1 summarises
the patient demographics and baseline characteristics.
Table 1 Demographics and Baseline Characteristics
Characteristic Result
Demographics
Values stated in median and (range)
Gender
Male 5/17 (29.4%)
Female 12/17 (70.6%)
Age at death (years) (N = 15); 63 (18–81)
Age at implant (years) (N = 17) 63 (18–81)
Height (cm) (N = 15) 164 (152–177)
Weight (kg) (N = 16) 69 (52–128)
BMI (kg/m2) (N = 14) 25.5 (18.2–41.3)
Aetiology of ascites: Primary Cancer Type
Ovarian 5/17 (29.4%)
Breast 1/17 (5.9%)
Uterine 1/17 (5.9%)
Pancreatic 1/17 (5.9%)
Hepatic 6/17 (35.3%)
Cholangiocarcinoma 2/17 (11.8%)
Renal 1/17 (5.9%)
Comorbidities of interest (predefined)
Cardiovascular disordersa 11/17 (64.7%)
Hepatobiliary disordersb 5/17 (29.4%)
Haematologic and lymphatic disordersc 3/17 (17.6%)
Endocrine disordersd 2/17 (11.8%)
Gastrointestinal disorderse 3/17 (17.6%)
Metabolic and nutritional disordersf 7/17 (41.2%)
Musculoskeletal and connective tissue disordersg 2/17 (11.8%)
Nervous system disordersh 1/17 (5.9%)
Respiratory, thoracic and mediastinal disordersi 1/17 (5.9%)
Skin and subcutaneous tissue disordersj 2/17 (11.8%)
a Chronic heart disease [2]; Hypertension [6]; Peripheral arterial disease; Other
[3]: Previous pulmonary embolus and cardiac arrest; Pulmonary embolism;
Ebstein’s anomaly
b Hepatitis C; Hepatocellular carcinoma, Cholangiocellular carcinoma, Cirrhosis;
Hepatic encephalopathy; cirrhosis; fibrolamellar hepatocellular carcinoma
c Idiopathic thrombocytopenic purpura; Progressive oedema; Chronic anemia
d Hypothyroidism; Hypothyreosis
e Duodenal ulcers, esophageal varices grade I, esophageal variceal bleeding;
Esophageal varices Grade I/II, portal hypertensive gastropathy;
Barrett Oesophagus
f Primary hyperparathyroidism; Diabetes mellitus type II, sarcopenic obesity;
Type 2 diabetes [2]; Malnutrition; Hypoalbuminemia; protein deficiency
g Sarcopenia; Bone metastases
h Pseudoradicular syndrome
i COPD, asthma
j Psoriasis
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Procedural characteristics
All procedures were conducted by a minimally invasive
approach under general anaesthetic with a median dur-
ation of 60 min (range: 30–270) and median post-
implantation length of hospital stay of 4 days (range: 2–
24). Standard peritoneal catheters were used in 82.4%
(14) of cases; the Medionics catheter in 11.8% [2] of
cases and in 1 case the catheter specification was not de-
scribed. 12 (70.6%) patients received routine periopera-
tive antibiotics; six of them (35.3%) were on long-term
antibiotic prophylaxis for their underlying condition.
Table 2 shows the procedural characteristics in detail.
Safety
Medical adverse events
Thirty days postoperative morbidity included seven ad-
verse events in 4 patients (23.5%): 2 patients presented
with an acute kidney injury (AKI) that resolved spontan-
eously after hydration (one AKI was associated with a
sepsis that was rather related to the underlying malig-
nancy than to the AP implantation). One further patient
with AKI and liver cancer experienced a variceal bleed-
ing causing death on day 10 post implantation. One pa-
tient experienced a wound dehiscence of the left
subcostal implantation pocket due to local infection but
no signs of systemic infection. The pump pocket was
refashioned and the wounds were successfully readapted
in local anaesthesia on postop day 10.
In terms of longer-term morbidity, there were 5 com-
plications in 2 patients occurring within the first 3
months and not considered as device deficiencies; 3 of
these occurred in 1 patient. Details of all medical adverse
events are given in Table 3.
Pump- related complications
Pump related complications within the immediate 30
days post-implantation period occurred in 2 patients
(11.7%); one pump blockage on days 2 and 18 and one
bladder catheter blockage in a further patient, that re-
solved through reintervention on day 1. In terms of
longer-term technical pump-related problems; there was
1 pump failure due to humidity ingress (moisture within
the pump electronics) on day 344 that led to a pump
exchange. Furthermore, 2 additional surgical reinterven-
tions occurred; 1 explantation of the entire pump (re-
moval of the entire AP-system from the patient) while
the patient was still alive (unknown reason) and 1 revi-
sion procedure due to blocking of the bladder catheter 1
day after implantation. Data are presented in overview in
Table 3.
Device performance
Eight of the fifteen patients (53.3%) with available data
needed regular LVP prior to AP-implantation. Of the 12
subjects with known LVP data post-implant, only one
patient required an LVP post AP-implantation and
hence there was a clear decrease of the required LVP
through the AP. The primary endpoint of time-to-first-
LVP was not calculable due to the scarcity of LVP post
implant.
Any volume paracentesis was calculable for 15/17 pa-
tients pre-implant and 9/17 patients post-implant, with a
median number of total paracenteses events of 4 (range;
1–15) per patient pre-implant, and a median of 1 (range;
0–1) events per patient post-implant (p = 0.005). Median
paracentesis events per 30-day month were 1.30 (range
0.00–4.10; n = 15) pre-implant, and 0.08 (range 0–1.2;
n = 10) post-implant (p = 0.059).
The overall volumes removed via paracentesis were
evaluable in 10 patients pre-implant with a mean volume
of 17.72 ± 12.66 L (median 13.05; range 5.90–44.80) and
post-implant in 9 patients (5 no paracentesis) with a
mean of 0.96 ± 1.53 L (median 0; range 0.0–4.9).
The overall median volume of ascites drained by the
AP was 28 L (range 1.0–638.6; N = 17) and the median
ascitic volume pumped daily was 303.6 mL/day (range:
5.6–989.3, N = 17). Table 4 summarises the volume
drained data.
In summary, only four patients needed an additional
post-implant drainage – of any volume- of their ascites.
Oncology related outcomes, pump survival and QoL
Median patient survival was 111 days (range: 10–715;
n = 17) and median device survival 89 days (range: 0–
715; 17/18 pumps) (Fig. 1). A total of 16/17 patients had
a pump still in-situ at final outcome of death or end of
the present study; in one patient the pump had to be
explanted.
Eleven patients received systemic and anticancer treat-
ment after AP-implantation within a median time of 31
days post implantation (range: 2–253 days). Three pa-
tients received palliative care alone, without any further
anticancer treatment. In 3 patients no exact information
was available on their further oncologic management.
Retrospective treating physician assessment of effect of
treatment on quality of life revealed that 8 of 14 (57.1%)
evaluable patients had an improved overall QoL in the
Table 2 Procedural Characteristics
Characteristic Result
Type of anaesthesia
General 17/17 (100%)
Median duration of impant procedure in min (range)
(N = 17)
60 (30–270)
Median length of hospital stay in days (range) (N = 17) 4 (2–24)
Prolonged hospitalisation for non-procedure related
reasons
6/17 (35.3%)
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post-implant period, in 3 (23%) there was no change,
only 2/14 (14.3%) patients were considered to have a
reduced QoL and one patient could not be assessed for
overall status. More details of the QoL scores with
respect to individual domains are given in Table 5. In
three patients no retrospective QoL analysis could be
performed due to lack of data.
Discussion
The present study represents the first systematic evalu-
ation of the AP- device for the palliative management of
MA across patients with various epithelial tumour types.
We could demonstrate a significant reduction of the re-
quirements for any volume and large volume paracen-
teses through the AP compared to the preimplantation
period. The surgical morbidity profile was acceptable
considering the high-risk profile of the treated patients.
Only four patients needed an additional post-implant
drainage of their ascites through an extra catheter.
Moreover, as per the evaluation of the treating physi-
cians, 71% of the patients experienced an improvement
in at least one domain of QoL such as tiredness, abdom-
inal bloating and pain, sleeping, shortness of breath,
appetite and nutritional status. A comparison of patient
survival between gynae and gastrointestinal cancers
would have provided a meaningful analysis, however, due
to the very small number of total patients, no separate
valid analysis for each cancer type could be performed.
These results encourage the consideration of the AP
device also outside the area of cirrhosis related ascites,
into the field of palliative cancer medicine, even though
further prospective studies are warranted. The safety and
efficacy data we have demonstrated in the present evalu-
ation are similar to the ones already established for cir-
rhotic patients. The experience on 56 cirrhotic patients
in a post market surveillance registry study demon-
strated within a median follow-up period of 5.8 months
a median reduction in post-implant paracentesis rate
from 2.17 to 0.17 events per month [12]. Additionally,
44 device and procedure related safety events were expe-
rienced, compared to 4 events in 4 (23.5%) patients in
the present study. Surgical reintervention was required
in 17 (21.4%) patients in the cirrhosis - replacement of
pump is not included - and in 3 (17.6%) patients in the
present study.
Nevertheless, the repetitive puncture and drainage of
the peritoneal cavity of patients with disseminated peri-
toneal carcinomatosis, in addition to being debilitating
for the patient, is also associated with significant poten-
tial risks such as bowel related complications, port/drain
Table 3 Medical adverse events – related or unrelated to the AP- implantation (NR: non-resolved)
A
Patient ID Adverse event Days after AP implantation Resolution day Day of last follow up or death
AP related
9 Wound dehiscence of the AP pocket 11 14 111
9 Infection 11 24 111
9 Peritonitis 47 60 111
9 Kidney Failure - Acute on chronic renal failure 2 24 111
11 Kidney Failure - Acute on chronic renal failure 8 NR 10
12 Kidney Failure - KDIGO AKI Stage 2 2 3 562
15 Infection - Sepsis + Acute on Chronic Kidney failure 8 NR 28
AP unrelated
3 Pleural effusion - chest drain and talc pleurodesis 33 42 81
3 Biliary duct stenosis 60 NR 81
9 Gastrointestinal bleeding 43 43 111
9 Kidney Failure - Acute on chronic renal failure 49 66 111
11 Variceal bleeding 8 Death 10
B
Patient ID Event Days after AP implantation Resolution day Day of last follow up or death
Technical issues
2 Pump blocked and in shake mode 2 8 53 (death)
4 Bladder catheter problem 1 1 45 (death)
8 Pump blocked and in shake mode 18 30 320 (death)
14 Pump problem, humidity problem 344 345 426 (death)
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related complications and infections. Further issues such
as loculation of the ascites result in ineffective palliative
drainage on the long term. Even though our experience
is mainly with PleurX, as the main approved treatment
modality for MA in the UK, there are numerous other
manufacturers across the various countries around
Europe. Their common feature is that they are semi-
permanent, are being inserted radiologically via usually
sonographic guidance and hence the risk of visceral in-
jury, especially in patients after extensive peritoneal sur-
gery with dense adhesions, is increased. Furthermore, in
immunosuppressed cancer patients, such external sys-
tems that are being exposed to constant manipulation
via the patients themselves or health personnel, are
potentially associated with higher risk of infections,
blockages and malfunction of the external part of the
catheter, that makes its clinical application often challen-
ging. Therefore, a closed system, without any direct
communication to external exposures has potentially a
lower risk of infection. Also, since it is being inserted
under direct vision, the risk of direct visceral injury is
lower.
As we confirmed in the present analysis, acute kidney
injury is a perioperative challenge that needs addressing.
For that reason, in a way forward, robust protocols
would need to be set in place to adequately replace
volume, during and immediately after the anaesthetic
procedure, under the perspective of a proactive manage-
ment. Since the patients are anyway hospitalized for a
few days post implantation, this fluid replacement can
occur under controlled circumstances in a safe environ-
ment even in this highly palliative setting.
Anecdotally, on the example of gynae cancer patients
alone, they did not report in clinical practice any pollaki-
suria (higher frequency of micturition) or dysuria that
would additionally negatively affect their QoL; just re-
ported higher volumes of urine released during voiding.
Nevertheless, this could not be not retrospectively
assessed and would need to be evaluated in any future
prospective study.
The present analysis has, nevertheless, significant
shortcomings which need to be considered when inter-
preting the data and therefore future prospective studies
are warranted to resolve these issues and answer still
open questions. The retrospective design on a multicen-
tre level had as a consequence the lack of completeness
of the requested data, especially in a population that has
in its majority deceased. This applies especially in the
QoL evaluation, which was just a retrospective estima-
tion of the treating physicians and hence requires further
exploration. The small sample, especially per cancer
type, led to only assumptive hypothesis regarding the
value of the pump on all patients with MA and therefore
more targeted and focussed studies need to be designed
Table 4 Comparison of Pre and Post-implant Paracentesis and LVP – Events and Volumes per Patient
N Median Q1 Q3 Mean Std Min Max
Prior to Implant
Paracentesisa
Event Rate (# Events/Months) 15 1.3 0.52 2.5 1.53 1.222 0 4.1
Volume Rate (Liters/Months) 10 6.78 2.96 12.05 7.89 6.026 1.8 21
Event Count 17 4 2 6 4.41 3.759 1 15
LVPb
Event Rate (# Events/Months) 6 1.93 1.36 3 11.45 23.797 0.5 60
Volume Rate (Liters/Months) 6 12.35 8.64 21 67.43 36.08 5.3 345
Event Count 8 2 1 4 2.5 1.69 1 5
Post Implant
Paracentesis
Event Rate (# Events/Months) 10 0.08 0 0.57 0.31 0.458 0 1.2
cVolume Rate (Liters/Months) 9 0.28 0 1.13 3.17 6.894 0 21
Event Count 10 1 0 1 0.6 0.516 0 1
LVP
Event Rated (# Events/Months) 1 1.07 1.07 1.07 1.07 . 1.1 1.1
cVolume Rate (Liters/Months) 1 5.36 5.36 5.36 5.36 . 5.4 5.4
Event Count 1 1 1 1 1 . 1 1
a includes LVP events and volumes. b Rates based upon observation period from first paracentesis to implant (not first LVP)
cVolumes calculated only for patients with known paracentesis events – patients with null events are not included
d Only one patient had an event – no data on frequency, timing, nor volume available
If Paracentesis’s data is missing but LVP’s is not missing, then LVP’s data is used for paracentesis
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to resolve the issues, challenges and effectiveness of the
pump in particular cancer types. A further drawback is
the lack of cost estimates in relation to the standard
treatment. Future studies will need to focus on the cost-
ing’s comparison of the relatively pricey pump compared
to the simple ascitic drainage and whether this is being
adequately counterbalanced with the gain from the re-
duced hospitalisation times, potential positive effect on
electrolyte disbalances, nutritional status of the treated
patients etc.
Even though our analysis has all these limitations, it
still may set the basis for a prospective multicentre
evaluation with the view of a broader potential imple-
mentation of the AP in oncology services. In cancer pa-
tients with liver cirrhosis, the pathophysiology of ascites
production may differ from patients with a peritoneal
carcinosis but preserved liver function. However, this
has not been specifically addressed in this retrospective
study. There is a prospective trial in planning with the
AP, so that more robust and valid data can be generated.
A significant aspect that needs to be addressed and
represents a potential concern of treating oncologists, is
the risk of implantation of malignant cells in the urinary
bladder mucosa with development of metastatic lesions
or even secondary cancers and the risk of recurrent
urinary tract infections (UTI) and stone formation/en-
crustation. With an average patient survival of only 3.5
months, and in view of the anyway diffusely dissemi-
nated disease, longer term events like a stone formation
or bladder cancerous lesions are rather clinically non-
relevant, even though that is at the present moment a
theoretical assumption. In the ovarian cancer cohort, the
Table 5 Retrospective QoL assessment by the treating physician (chart review)
Characteristics Worsened No change Improved No information
How did the alfapump affect the patient’s:
Tiredness 2/14 (14.3%) 5/14 (35.7%) 5/14 (35.7%) 2/14 (14.3%)
Abdominal pain 1/14 (7.1%) 2/14 (14.3%) 10/14 (71.4%) 1/14 (7.1%)
Sleeping 1/14 (7.1%) 3/14 (21.4%) 4/14 (28.6%) 6/14 (42.9%)
Bloating 1/14 (7.1%) 0/14 (0%) 8/14 (57.1%) 5/14 (35.7%)
Shortness of breath 1/14 (7.1%) 4/14 (28.6%) 7/14 (50.0%) 2/14 (14.3%)
Appetite 2/14 (14.3%) 6/14 (42.9%) 5/14 (35.7%) 1/14 (7.1%)
Nutritional status 3/14 (21.4%) 6/14 (42.9%) 3/14 (21.4%) 2/14 (14.3%)
Overall status 2/14 (14.3%) 3/14 (21.4%) 8/14 (57.1%) 1/14 (7.1%)
Fig. 1 Patient and Pump Survival Kaplan-Meier
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majority of the patients underwent a diagnostic cystos-
copy in the first 4–6 weeks post AP- implantation and
none of the patients showed bladder mucosal abnormal-
ities. No bladder biopsy was performed if the mucosa
was macroscopically normal, since any microscopic
mucosal infiltration was without clinical significance or
consequences. In the designing of a future prospective
study, routine cystoscopies should be considered to es-
tablish and confirm these initial observations. Neverthe-
less, in this highly palliative setting with limited patient
survival, secondary microscopic bladder wall seeding is
relative and has to be put in context with the overall
clinical picture of a diffuse peritoneal dissemination.
A further and potentially promising aspect of the AP
technology is the prospective of forming the basis of a
translational platform with a non-invasive, continuous
and biomolecular profiling in epithelial cancers during
antineoplastic treatment. Through the tumour cell
harvest from the urine we could theoretically have a
continuous, non-invasive, access to a liquid biopsy of the
patients that could be used for drug resistance testing
and mutational profile analysis [13]. How realistic and
feasible such an approach would be, needs to be ad-
dressed in future studies.
Conclusion
We could demonstrate in this retrospective analysis, that
AP appears to be relatively effective and safe in palliating
patients with MA, while seemingly improving their QoL.
Its implantation is rather straightforward and minimally
invasive, resulting in reduced necessity of repetitive
ascitic drainages, so that its broader implementation in
oncology services should be further explored in prospective
and comparative clinical trials to establish its value. A pro-
spective trial is currently in planning to compare standard
practice techniques with the AP including comparative
analysis of cost effectiveness, prospective evaluation of QoL,
impact on patients nutritional and metabolic status and
overall wellbeing.
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